Page 81 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

Table 1. Baseline characteristics from patients included in the analysis
Characteristics n=136
Predictors of benefit from high altitude treatment
Age (yrs)
Female gender (n(% n)) Age asthma onset (yrs) Ever smoker (n(% n))
Domains:
1. Medication
Use of OCS (n(% n)) OCS dose (mg/day) ICS dose (mcg/day)
2. Patient reported outcomes
AQLQ score
ACQ score SNOT-20 score CIS-Fatigue score
3. Lung function
FEV1 post ß2 (L) FEV1 post ß2 (%) 6MWD (m)
4. Airway inflammation
Blood eosinophils (unit/μl) FeNO (ppb)
Atopy (n(% n))
Total IgE (kU.L-1) Sensitization HDM (n(%n))
5. Life style
BMI (kg/m2)
45.9 92.0 8.5 51.0
72.0 20.0 1000
3.87 3.16 2.20
50.0
2.87 89.29 460.0
180.0 19.0 90.0 112.0 65.0
28.8
(36.0 to 56.0) (67.6)
(2.6 to 26.7) (37.0)
(53.0)
(10.0 to 30.0) (500 to 1000)
(3.18 to 4.57) (2.66 to 3.83) (1.67 to 2.75) (44.0 to 55.0)
(1.9 to 3.2) (68.3 to 100.7) (373.0 to 560.0)
(92.5 to 337.5) (11.0 to 40.0) (66.0)
(32.4 to 384.7)
(47.7)
(28.0 to 32.9)
unless otherwise stated.
Footnote table 1. Data are presented as median (interquartile range)
79
4